DEAN RUTZ / THE SEATTLE TIMES

Previous | 1 of 2 | Next

CellCyte shares ride a wave of hype

Gary Reys, CellCyte Genetics chief executive, says the skyrocketing trading volume is an "amazing" show of investor confidence in its technology for manipulating stem cells.

More photos | Most viewed | Purchase photos

© 2007 The Seattle Times Company